Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxtran-10-enhanced MRI for Pelvic Lymph Node Metastases in High-risk Prostate Cancer
DRKS00019106Phase 3Completed
- Sponsor
- Saving Patients' Lives Medical B.V.
- Start
- Feb 2020
- Modality
- Nanoparticles → Drug Delivery Systems
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of ferumoxtran-10 in prostate cancer (PCa), sponsored by Saving Patients' Lives Medical B.V. Primary endpoint: Diagnostic accuracy of Ferumoxtran-10-enhanced MRI for detection of pelvic lymph node metastases compared with histopathology. Started Feb 2020; status: completed.
02
Drugs
ferumoxtran-10
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on DRKS00019106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00019106.